Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E
IRCCS Ospedale San Raffaele, Obstetrics and Gynecology Department, Milan, Italy.
Gynecol Oncol. 2008 Feb;108(2):332-5. doi: 10.1016/j.ygyno.2007.10.021.
Palmar-plantar erythrodysesthesia (PPE) is a characteristic cutaneous toxicity associated with pegylated liposomal doxirubicin (PLD). Different therapies have been proposed to alleviate PPE onset. We performed a prospective study to evaluate preventive strategies to reduce PPE incidence in patients treated for gynecologic cancers.
Fifty-three patients were treated from 2001 to 2006 with PLD as single agent therapy or in combination with carboplatin or paclitaxel. PLD dosages were in the range of 30-50 mg/m2 every 21-28 days. All patients received premedication with dexamethasone and pyridoxine. Twenty-eight patients received application of ice packs on extremities during PLD infusion.
PPE was observed in 11 patients (20.8%). PLD administration as single agent or in combination and schedule of PLD therapy did not affect PPE incidence. A significant reduction in PPE onset was observed if PLD dosage was 30-35 mg/m2 (p=0.03) and when patients were submitted to regional cooling protocol (p=0.0097).
The use of ice packs around wrists and ankles is a simple and well tolerated prevention strategy and its efficacy is demonstrated in this study.
手足红斑性感觉异常(PPE)是聚乙二醇化脂质体阿霉素(PLD)相关的一种特征性皮肤毒性反应。人们提出了不同的治疗方法来减轻PPE的发生。我们进行了一项前瞻性研究,以评估预防策略对降低接受妇科癌症治疗患者PPE发生率的效果。
2001年至2006年期间,53例患者接受了PLD单药治疗或与卡铂或紫杉醇联合治疗。PLD剂量为每21 - 28天30 - 50mg/m²。所有患者均接受了地塞米松和吡哆醇的预处理。28例患者在PLD输注期间接受了四肢冰敷。
11例患者(20.8%)出现了PPE。PLD单药治疗或联合治疗以及PLD治疗方案均未影响PPE发生率。当PLD剂量为30 - 35mg/m²时(p = 0.03)以及患者接受局部降温方案时(p = 0.0097),观察到PPE的发生显著减少。
手腕和脚踝周围使用冰袋是一种简单且耐受性良好的预防策略,本研究证实了其有效性。